Overcoming Cancers Resistant to Her 2 Antibodies

Overcoming Cancers Resistant to Her 2 Antibodies
Author: Benjamin Bonavida
Publsiher: Sensitizing Agents for Cancer
Total Pages: 250
Release: 2019-12-15
ISBN 10: 9780128164082
ISBN 13: 0128164085
Language: EN, FR, DE, ES & NL

Overcoming Cancers Resistant to Her 2 Antibodies Book Review:

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
Author: Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publsiher: Springer
Total Pages: 320
Release: 2019-07-15
ISBN 10: 303021477X
ISBN 13: 9783030214777
Language: EN, FR, DE, ES & NL

Current Applications for Overcoming Resistance to Targeted Therapies Book Review:

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
Author: Benjamin Bonavida
Publsiher: Springer Science & Business Media
Total Pages: 202
Release: 2013-08-04
ISBN 10: 1461476542
ISBN 13: 9781461476542
Language: EN, FR, DE, ES & NL

Resistance to Immunotherapeutic Antibodies in Cancer Book Review:

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Targeted Therapies in Breast Cancer

Targeted Therapies in Breast Cancer
Author: George W. Sledge, Jr.,Jose Baselga
Publsiher: Unknown
Total Pages: 100
Release: 2013-04-15
ISBN 10: 9781846920660
ISBN 13: 1846920663
Language: EN, FR, DE, ES & NL

Targeted Therapies in Breast Cancer Book Review:

This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.

Cancer Chemotherapy and Biotherapy

Cancer Chemotherapy and Biotherapy
Author: Bruce A. Chabner,Dan L. Longo
Publsiher: Lippincott Williams & Wilkins
Total Pages: 848
Release: 2011-12-07
ISBN 10: 1451148208
ISBN 13: 9781451148206
Language: EN, FR, DE, ES & NL

Cancer Chemotherapy and Biotherapy Book Review:

Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.

HER2 Positive Breast Cancer

HER2 Positive Breast Cancer
Author: Sara Hurvitz,Kelly McCann
Publsiher: Elsevier Health Sciences
Total Pages: 264
Release: 2018-07-26
ISBN 10: 0323581234
ISBN 13: 9780323581233
Language: EN, FR, DE, ES & NL

HER2 Positive Breast Cancer Book Review:

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Translational Research in Breast Cancer

Translational Research in Breast Cancer
Author: Dong-Young Noh,Wonshik Han,Masakazu Toi
Publsiher: Springer Nature
Total Pages: 630
Release: 2021-05-13
ISBN 10: 9813296208
ISBN 13: 9789813296206
Language: EN, FR, DE, ES & NL

Translational Research in Breast Cancer Book Review:

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.

Monoclonal Antibodies Advances in Research and Application 2012 Edition

Monoclonal Antibodies   Advances in Research and Application  2012 Edition
Author: Anonim
Publsiher: ScholarlyEditions
Total Pages: 105
Release: 2012-12-26
ISBN 10: 148160516X
ISBN 13: 9781481605168
Language: EN, FR, DE, ES & NL

Monoclonal Antibodies Advances in Research and Application 2012 Edition Book Review:

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Cancer Cell Signaling

Cancer Cell Signaling
Author: Kasirajan Ayyanathan
Publsiher: CRC Press
Total Pages: 410
Release: 2014-06-20
ISBN 10: 1482299453
ISBN 13: 9781482299458
Language: EN, FR, DE, ES & NL

Cancer Cell Signaling Book Review:

This title includes a number of Open Access chapters. Cell signaling is a field that studies how cells communicate to control basic activities and respond to their environment. When looking specifically at cancer cells, researchers can gain a better understanding of cancer on a cellular level, an understanding that may have implications for developing new treatments. The current volume provides an overview of the field and how various cell biology techniques are used to better understand cancer on a cellular level. This easily accessible reference volume offers a comprehensive look at the field of cancer cell signaling. Edited by a researcher from Florida Atlantic University, Cancer Cell Signaling: Targeting Signaling Pathways Towards Therapeutic Approaches to Cancer is an authoritative and easy-to-use reference.

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Academic Press
Total Pages: 388
Release: 2021-08-11
ISBN 10: 0128243007
ISBN 13: 9780128243008
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Central Nervous System Metastases

Central Nervous System Metastases
Author: Manmeet Ahluwalia,Philippe Metellus,Riccardo Soffietti
Publsiher: Springer Nature
Total Pages: 421
Release: 2019-11-05
ISBN 10: 3030234177
ISBN 13: 9783030234171
Language: EN, FR, DE, ES & NL

Central Nervous System Metastases Book Review:

This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab
Author: Banujan Balachandran
Publsiher: Unknown
Total Pages: 135
Release: 2013
ISBN 10: 1928374650XXX
ISBN 13: OCLC:922055022
Language: EN, FR, DE, ES & NL

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab Book Review:

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination therapies. However, the majority of advanced HER-2 positive breast cancer patients still develop resistance to the therapy by the end of the first year or present de novo resistance. For this reason, it is important to continue to investigate therapies to give in combination with trastuzumab to improve progression-free survival and overall survival in this clinical setting. Two Phase II Astra Zeneca compounds: AZD0530, a dual Src and Abl kinase inhibitor and AZD8931, a pan-erbb tyrosine kinase inhibitor abrogating EGFR-, HER-2-, and HER-3-mediated signaling were explored in this context using established trastuzumab-naïve and trastuzumab-resistant cell lines. AZD0530 was not effective when administered alone and any combinations with trastuzumab showed positive responses only in those models in which some form of response to AZD0530 alone had been seen. Clinically-relevant responses to AZD8931 were seen in all cell lines tested and for this reason a head-to-head comparison was carried out with lapatinib, the FDA-approved therapy for patients progressing on trastuzumab. AZD8931 alone and in combination with trastuzumab worked effectively to stop proliferation and induce cell death in both trastuzumab-naïve and trastuzumab-resistant cell lines at clinically relevant doses. AZD8931 had similar activity to lapatinib in the SKBR3-based ER-negative cell lines, but was less active in the BT474-based ER-positive cell lines. From this study, it appears AZD8931 is a therapeutic candidate for overcoming trastuzumab resistance but further investigation is required, before translation into the clinical setting, including the use of animal models of trastuzumab-resistance, specifically in the ER-negative subtype." --

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
Author: Goli Samimi,Christina Annunziata
Publsiher: Academic Press
Total Pages: 188
Release: 2020-11-06
ISBN 10: 0128198419
ISBN 13: 9780128198414
Language: EN, FR, DE, ES & NL

Overcoming Ovarian Cancer Chemoresistance Book Review:

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Translational Medicine

Translational Medicine
Author: Robert A. Meyers
Publsiher: John Wiley & Sons
Total Pages: 940
Release: 2016-04-29
ISBN 10: 3527681868
ISBN 13: 9783527681860
Language: EN, FR, DE, ES & NL

Translational Medicine Book Review:

The first complete overview of progress in the field. The two volumes contain selected articles from the prestigious online Encyclopedia of Molecular Cell Biology and Molecular Medicine, fully updated and enriched with numerous new contributions from many eminent scientists. Divided into three parts, the first gives a thorough introduction to cancer biology, while Part Two covers therapeutic approaches for all major forms of cancer, and the third part deals with cancer diagnostics. The result is a one-stop resource for advanced students, postdoctoral researchers and start-up companies.

Resistance to Targeted Therapies in Breast Cancer

Resistance to Targeted Therapies in Breast Cancer
Author: Jenifer R. Prosperi
Publsiher: Springer
Total Pages: 184
Release: 2017-12-04
ISBN 10: 3319701428
ISBN 13: 9783319701424
Language: EN, FR, DE, ES & NL

Resistance to Targeted Therapies in Breast Cancer Book Review:

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.

Resistance to Targeted Therapies in Multiple Myeloma

Resistance to Targeted Therapies in Multiple Myeloma
Author: Silvia CW Ling,Steven Trieu
Publsiher: Springer Nature
Total Pages: 154
Release: 2021-07-23
ISBN 10: 3030734404
ISBN 13: 9783030734404
Language: EN, FR, DE, ES & NL

Resistance to Targeted Therapies in Multiple Myeloma Book Review:

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

Breast Cancer

Breast Cancer
Author: Mehmet Gunduz,Esra Gunduz
Publsiher: BoD – Books on Demand
Total Pages: 746
Release: 2011-11-30
ISBN 10: 953307714X
ISBN 13: 9789533077147
Language: EN, FR, DE, ES & NL

Breast Cancer Book Review:

Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.

Handbook of HER2 targeted agents in breast cancer

Handbook of HER2 targeted agents in breast cancer
Author: Ricardo H Alvarez,Javier Cortés,Leticia Mattos-Arruda,Mary Falzon,Angelica Fasolo,Michael Gandy,Luca Gianni,Nadia Harbeck,Martine Piccart,Stefania Zambelli,Dimitrios Zardavas
Publsiher: Springer
Total Pages: 96
Release: 2014-05-28
ISBN 10: 1907673946
ISBN 13: 9781907673948
Language: EN, FR, DE, ES & NL

Handbook of HER2 targeted agents in breast cancer Book Review:

​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

Targeted Cancer Therapies From Small Molecules to Antibodies

Targeted Cancer Therapies  From Small Molecules to Antibodies
Author: Zhe-Sheng Chen,Jian-ye Zhang,Yunkai Zhang,Yan-yan Yan
Publsiher: Frontiers Media SA
Total Pages: 135
Release: 2020-07-22
ISBN 10: 2889638847
ISBN 13: 9782889638840
Language: EN, FR, DE, ES & NL

Targeted Cancer Therapies From Small Molecules to Antibodies Book Review:

Innovations for Next Generation Antibody Drug Conjugates

Innovations for Next Generation Antibody Drug Conjugates
Author: Marc Damelin
Publsiher: Springer
Total Pages: 357
Release: 2018-05-29
ISBN 10: 3319781545
ISBN 13: 9783319781549
Language: EN, FR, DE, ES & NL

Innovations for Next Generation Antibody Drug Conjugates Book Review:

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.